Archive for December, 2019

Acne vulgaris is a common, usually self-limiting, multifactorial disease that involving inflammation of the sebaceous follicles of the skin in the face and upper trunk.

Acne is a chronic, inflammatory skin condition that results in spots and pimples, especially on the face, shoulders, back, neck, chest, and upper arms.

The following are the most common types of acne;

During puberty, the sebaceous gland is activated so there are more chances of developing acne in that stage, but it can occur at any age. It is not dangerous, but it can cause;

Acne usually occurs when hair follicles become plugged with oil and dead skin cells. Bacteria worsen the condition by causing infection and inflammation.

During puberty increased androgen activity triggers the growth of sebaceous glands which results in enhanced sebum production.

The four primary factors involved in the formation of acne are;

The most common Risk factors for acne are as follows;

During puberty, there are more levels of testosterone in the body. Testosterone enhances the production of sebum from a sebaceous gland that results in acne.

Acne in females

Hormonal changes in female occur during;

Diagnosis of Acne

Diagnose of acne can be done by careful examination of the skin. It involves examination of face, chest or back for the different types of spots, such as blackheads or sore, red nodules.

Treatment of acne involves the use of Topical and Oral preparations. The goal of treatment is to prevent the formation of new acne lesions, heal existing lesions, and prevent or minimize scarring.

Topical preparations for acne include;

These preparations are used for Mild to moderate acne, comedones, and inflamed lesions.

Benzoyl peroxide

Benzoyl peroxide (Benzac AC, Acnestar ) is effective against;

Treatment is usually started with low strength; if acne does not respond to the treatment after 2 months then topical antibacterial is recommended.

Azelaic Acid

Azelaic Acid (Aziderm) is effective against;

It has antimicrobial and anticomedonal properties. It causes less local skin irritation as compared to benzoyl peroxide.

Topical Antibacterial

Topical erythromycin and clindamycin are used against;

These are usually recommended to avoid the oral use of antibacterial.

To avoid antibacterial resistance;

Topical Retinoid

Topical retinoid is effective against;

Retinoid (TRETINOIN) and Adapalene (ADACLENE) are used as a topical retinoid.

Treatment with topical retinoid should be continued for several months until no new lesions are formed.

Oral preparations for acne include;

Systemic antibacterial treatment

Systemic antibacterial used for the treatment of acne are as follows;

Oral Hormone Treatment

Co-cyprindiol (an Oral Hormone), is used for the treatment of moderate to severe acne. It has anti-androgen properties. Sebum secretion and hair growth depend on androgen. Co-cyprindiol decreases sebum secretion and it is also used for hirsutism.

Oral hormone treatment is recommended to treat moderate to severe acne in the female.

It is recommended when topical and oral antibacterial therapy does not produce the desired outcome.

Co-cyprindiol also has contraceptive properties.

Oral Retinoid

Oral Retinoid used for the treatment of acne is isotretinoin. It reduces sebum secretion. Isotretinoin is used for the systemic treatment of;

Isotretinoin is useful in women who develop acne in the third or fourth decades of life. Since acne in this age is usually not responsive to antibacterial. Isotretinoin is given for at least 4 months (16 weeks).

Side-effects of isotretinoin include;

Isotretinoin is teratogenic and must not be given to pregnant women. Treatment with Isotretinoin should be stopped if psychiatric changes occur during treatment.

Visit https://www.drugscaps.com/product-category/face-care/ to find products online.

Home Remedies

Below mentioned are some home remedies for acne;

Tea tree oil Tea tree extract has natural antibacterial and anti-inflammatory properties. Teat tree oil can be added in creams, gels, or essential oil.

Jojoba oil Waxy substances in jojoba oil helps to repair skin. Jojoba oil can be added in creams, gels, essential oils, and clay face masks. It can also be applied directly to acne sore with the help of a cotton pad.

Aloe Vera Aloe Vera has antibacterial and anti-inflammatory properties. Aloe Vera can be added to creams or gels.

Honey Honey has anti-oxidant properties that help to clear clogged pores from debris. Honey can be directly applied to pimples using a cotton pad or a clean finger.

Green Tea Green tea contains antioxidants. Green tea extract can be applied to the skin or it can be used as a drink.

Visit https://www.drugscaps.com/product-category/face-care/ to find products online.

References

Dermatological Disorders In Current Medical and Diagnosis Treatment. Mc Graw-Hill Education, 55th Edition, 2016. (page: 127-129)

Acne Vulgaris In Pharmacotherapy Handbook. The McGraw-Hill companies, 7th edition, 2009. (page: 179-185)

Melnik, B. C. (2015, July 15). Linking diet to acne metabolomics, inflammation, and cosmogenesis: An update. Clinical, Cosmetic, and Investigational Dermatology, 8, 371388ncbi.nlm.nih.gov/pmc/articles/PMC4507494/

Go here to read the rest:
Hair Loss Treatment Through Cupping Therapy (Hijama) At Health and Hijama Clinic Bangalore! - The Hear UP

There is an ongoing debate about what is included in the definition of Femtech, and the need to think beyond reproductive health and make the field more inclusive. However, there is power in using terminology that creates visibility for concepts or issues that have long been widely overlooked. Femtech has and continues to serve the purpose of creating a catchy reference to a business sector that primarily addresses the health and wellness needs of women -and people who experience similar health issues- through software, diagnostics, products and tech-enabled health services.

As this category continues to grow and be fueled by unwavering founders, investors and leaders, its impact is expanding beyond healthcare and into other domains, from workplace regulations, to advocacy against gender biases in advertising, from financial equity to state legislation.

2019 was an inflection point for this space which is on the path to becoming a consolidated $50 billion dollar industry (estimated for 2025 by F&S), while improving the lives of millions of women and their communities. To celebrate the accomplishments of leaders and visionaries who persisted, even after hearing for the hundredth time that the problems they were solving were too niche, heres a selection of the trends and highlights in Femtech in 2019.

Graphic by Vanessa Larco, Partner at NEA. $310M represents mid-year; $730M represents investment at ... [+] publishing date.

1. The Fertility Space Is Ready To Harvest What It Sow

Data Bridge, a research firm, predicts that by 2026 the booming global fertility industry could reach $41bn in sales, from approximately $25bn this year. No wonder investors are writing checks.

Manhattan based Extend Fertility brought in new talent into their leadership team, announced a $15 million Series A and total rebrand. Competitor egg-freezing and fertility clinic Kindbody also raised $15 million earlier this year, plus another $10 million from GV last week, totalling $31.3 million in capital raised. The company plans to support employers in offering better fertility benefits to their employees.

Nextgen Jane, a data-driven health company for women and people who menstruate, raised $9 million Series A. Its smart tampon platform allows users to collect menstrual and cervicovaginal samples and ship them off to a lab for in-depth analysis and disease detection.

2. At-home Testing Grows As Modern Consumers Demand Convenience And Affordability

Modern Fertility announced a $15 million funding round led by Forerunner Ventures to expand its affordable at-home hormone testing service and continue to collect anonymous data to contribute to womens health research and product development

Consumer lab testing platform Everlywell, which also provides womens health testing, raised $50 million this spring. The Texas-based company serves hundreds of thousands of customers, simplifying the often cumbersome and confusing diagnostic lab testing process.

3 . Female Founders Took A Stance Against Reproductive Health Bans, Unlocking Support From 200 CEOs

The initial 7 signing CEOs included Cora, Dame, Thinx, Sustain, Clary Collection, Fur and Loom. In their NYTs open letter they demanded that the CEOs of companies that use feminism and womens empowerment as marketing arsenal take a stance for womens rights, following the passing of bills restricting access to reproductive health services in several states. Weeks later, almost 200 CEOs and executives supported the movement under: Dont Ban Equality. The participating organizations and executives included big household names like H&M, tech entrepreneurs including MakeLoveNotPorns Cindy Gallop and Unbounds Polly Rodriguez, wellness founders Emily Weiss from Glossier and OUAIs Jen Atkins, and prominent investors such as Anu Duggal from Female Founders Fund and Wests Joanna Rees.

4. The Power of Community Support And Science In The Preconception Period

When it comes to maternal health, the conversation mostly revolves around (successful) pregnancy and motherhood. However, the ups and downs of the preconception journey are often left out of the conversation, causing many to feel lost and isolated.

Peanut, the social network for mothers, announced a $5 million funding round and the launch of TTC, a new site within Peanut specifically designed for the needs of women who are trying to conceive. Additionally, former CEO of RockHealth Halle Tecco launched Natalist and raised $5 million to address the gap in the market for better designed products and a more intelligent platform that supports the preconception journey.

5. Finance Meets Femtech To Increase Access To Family Planning

Cost is still the main barrier to access to fertility treatment, as explained in this white paper of the American Society for Reproductive Medicine. 80% of people who undergo fertility treatment have little to no coverage and accrue an average of $30k in debt.

Fertility benefits company Carrot Fertility launched its Visa Carrot Card early this fall, the first fertility debit card for employees who have access to Carrot at work that makes it easy for employees to pay for treatment like egg freezing, IVF, and adoption, among other services.

Future Family aims to tackle the problem offering personalized financing plans for IVF and egg freezing, under a subscription payment model. Future Family recently announced that it will be offering free fertility testing for all members.

6. Menstrual Wellness Management Keeps Growing And Celebrates Two Exits

This is L. and competitor Sustain were both acquired this year by P&G and Grove Collaborative, respectively. This is L.s deal is said to be around the $100 million.

San Francisco-based Cora, which sells organic personal care items closed a $7.5 million Series A led by Harbinger Ventures. Additionally, femcare meets CBD, the darling wellness category of the year, in Daye, a startup that has developed a new type of tampon to help tackle dysmenorrhea. It raised $5.5 million this year, led by Khosla Ventures.

There is in fact a growing interest in the intersection of menstrual health and pain management that startups like FLO Vitamins and Elix are also tackling.

7. Digital Health Attracting Consumers Who Want A Better Experience

Navigating healthcare is a burdensome process that Millennials and Gen Z mostly dread and that can put people at risk due to health concerns that arent properly addressed.

Tia Clinic started as a digital womens health solution and has now gone brick and mortar. The startup opened its first location in NYC this year and memberships sold out in the first few weeks. Allbodies launched with the mission of covering the reproductive and sexual health questions and needs of all people, particularly addressing those areas that are still highly stigmatized.

Going back to the subject of inclusivity, Queerly Health, a digital health startup democratizing access to LGBTQ+ health and wellness, has had its first launch in NYC. Queerly Health will be linking LGBTQ+ inclusive providers with gay women, queer women, trans women, and gender variant folks (who may be assigned female at birth), among others. As explained by CEO Derrick Reyes, Queerly Health recently started enrolling providers in NYC and will be available to the public in 2020.

8. Progyny became the first fertility benefits company to ever IPO

Family benefits company Progyny (PGNY) went public on October 25. At the offering price, Progyny raised $130 million, and reached a fully diluted market value of $1.3 billion.

Fertility benefits coverage is consolidating as a must-have as more studies reflect that this is a key element in talent retention and employee satisfaction -62% of employees who had their IVF sponsored by their employer expressed that they were more likely to stay longer with the company.

9. One Billion in Funding: Investors Are Watching

Frost & Sullivans report stating that Femtech would reach $50 billion value in the next 5 years, paired up with the recent wins by leading companies and the awareness generated by the female entrepreneur community, has helped the space get on the radar of prominent investors. Just to name another example, Mahmee, a startup tackling the maternal health crisis, announced a $3 million round that included Serena Williams, Arlan Hamilton and Mark Cuban as investors.

This year the space surpassed $1 Billion in total funding since 2014. According to data provided by venture capitalist Vanessa Larco, Partner at NEA, this years total funding in the Femtech category falls just short of $750 million. Larco, who sits on the board of Cleo, a fertility to parenting employee support system, is a firm supporter of the space and hopes to see more exits in the near future: We need the investment community to see that you can make money while making a positive impact on womens health. The bigger the exits, the more money gets invested in the space, and the more companies we will see that should drive better outcomes. Its really the boost we need to get the flywheel going. Thats how you get a venture-funded industry going. And Im eager to see this happen as a woman and investor.

A celebrated funding round this year Elvies $42 million Series B led by IPGL, which was labeled as the largest in Femtech. In all fairness, this is strictly the largest funding round by a female founded Femtech company. However, if we look at the total market, we see that out of the 4 biggest funding rounds in Femtech, 3 were raised by companies founded and built by men (Nurx, Hims/Hers, Ro/Rory). In fact, two of these four were initially mens health companies, primarily selling on-demand pharma products, that then launched women-centered verticals (Hims/Hers, Ro/Rory).

10. Audioerotica Is Bringing Sexy Back

Think inclusive erotica and porn meet sexual wellness. Four companies aim to revolutionize the way people, and specially women, perceive and consume erotic content: Quinn, Dipsea ($ 5.5 million raised), Ferly, and Emjoy all have created digital platforms where audio is the main format, and science and a deep understanding of womens psychology are key elements.

This is part of a larger trend led by rising intimate and sexual wellness startups made by women for women that are creating safe spaces for sexual health education and conversation, while also transforming the way society views womens sexuality at every different stage in life.

Another female-founded startup addressing womens sexual health is Rosy, a digital health solution that supports women experiencing low libido.

11. Maternity And The Workplace: Transforming Culture Through Innovation

The struggle of juggling being a parent and thriving in the workforce is real, especially for women. The work/house role division is no longer set in stone, and employers need to think about supporting womens return after pregnancy and offering fathers the right to extended parental leave.

This creates an opportunity for technology to help reduce existing frictions. Companies innovating in the working mother space include wearable, silent breast pump makers like Elvie or Willow, lactation digital health solutions and communities like Pumpspotting, postpartum telemedicine and parenting benefits like Maven and Cleo, and milk shipping services like Milk Stork for lactating employees that need to travel for work.

12. Destigmatizing Menopause

Out of all of the life stages a woman goes through, menopause is probably the most overlooked by society. Ageism has made women practically invisible in the media after 45, and it transpires into the way we think about healthcare in perimenopause and menopause.

Gennev is an online clinic dedicated exclusively to this stage of life. Founder and CEO Jill Angelo raised $4 million this year and is excited to be launching an annual Zeitgeist study on menopause based on a survey of 6,000, the largest of its kind. Angelo adds that as women live longer and have more wealth than ever, they demand more information about their bodies and they want more care options whether that be traditional hormone therapy or lifestyle-based options for relief.

Elektra Health is another platform for women navigating perimenopause & menopause. Over 80% of women suffer debilitating symptoms (anxiety/depression, brain fog, hot flashes...) as a result of hormonal menopausal shifts, yet 75% of those who seek care dont receive it. Elektra is organizing monthly salon events with leading experts and, starting in 2020, will provide a virtual clinic for New York-based patients.

13. CPG Giants, Pharma, Insurers and Accelerators Make Moves Into The Space

P&G Ventures partnered with Vinetta project earlier this year to source its next billion dollar brand from the community of entrepreneurs, and has expressed a strong interest in the menopause space as well as aging.

Johnson and Johnson has been co-sponsoring innovation summits with a focus on womens health. Additionally, J&J has partnered with accelerator Founders Factory, which is launching a health hub in NYC. The project will be headed by former Techstars Managing Director Maya Baratz Jordan, and is said to focus initially on womens health.

Finally, Pharma companies are paying attention as DTC birth control startups like PillClub, Nurx and Simple Health gain traction among consumers. Insurer Axa, on the other hand, recently announced it will be selecting a group of women entrepreneurs for its first Femtech acceleration program.

Growing amounts of funding, acquisitions, Series A and B, growing consumer demand, and the attention of the biggest healthcare players... It all points out to an exciting 2020. Any bets? Ill be sharing some investor takes on whats to come in the next article.

More:
Femtech in 2019: 13 Trends And Highlights In Womens Health Technology - Forbes

If there's one part of the body that most people would like to be free of excess fat, it's the belly. And it's not just for appearance's sake: The specific type of fat that accumulates around your midsection has been linked to a higher risk of disease, including some cancers, type 2 diabetes and heart disease.

Core exercises can reduce the appearance of belly fat, but there are better ways to get rid of it altogether.

Credit: andresr/E+/GettyImages

Spot reduction, or the idea that you can target fat loss from specific areas of the body, is a myth, so there's no exercise or food that will magically melt away belly fat. But if you're looking to lose belly fat for the long haul, there are a number of research- and expert-backed things you can do.

The first step to getting rid of your belly fat is understanding how it's different from other types of body fat and how that factors in when it comes to weight loss.

There are two types of belly fat:

"As we get older and our hormones change, we tend to deposit more visceral fat, which is very pro-inflammatory and much more dangerous to health than subcutaneous fat," Luiza Petre, MD, a cardiologist and weight-management expert, tells LIVESTRONG.com.

Generally, a waist size over 35 inches for women and over 40 inches for men indicates excess visceral fat, according to the National Institutes of Health.

First things first: Weight loss is a systemic process, which means that energy (read: fat) is burned at an equal rate throughout the body, Dr. Petre says. In other words, your body doesn't tap any one particular area before any other.

"What may seem to be focal weight loss is actually a product of how our fat tissue is distributed," she explains. Women tend to store more fat around the thighs and hips, while men carry more around the waist. Therefore, when weight loss occurs, it's more visible in those areas.

However, there is a difference when it comes to which type of fat goes first. Visceral fat is more readily metabolized into fatty acids, per Harvard Health Publishing, so it responds to diet and exercise more efficiently than soft fat on, say, the hips and thighs.

Once you create a healthy calorie deficit and implement the tips below, you can expect to see a difference in your belly in about two weeks.

Credit: Chaloemphon Wanitcharoentham / EyeEm/EyeEm/GettyImages

How quickly can you expect to watch your belly disappear? Well, that all depends on your calorie deficit.

If you want to lose belly fat, you need to lose weight, which means you need to consume less calories than you burn. Most people can safely cut between 500 and 1,000 calories per day, which typically leads to between 1 and 2 pounds of weight loss per week, according to the Mayo Clinic.

Wondering how to calculate your calories for weight loss? Download the MyPlate app to do the job and help you track your intake, so you can stay focused and achieve your goals!

If you stick to that schedule, you should start to notice a difference in your abdominal area in about two weeks, says Holly Roser, a certified personal trainer and sports nutritionist.

Don't fall for fads promising lightning-fast weight loss or six-pack abs in just a few days. Here's what really works when it comes to trimming your tummy and keeping visceral fat at bay.

Try High-Intensity Interval Training (HIIT)

When you think about exercise for a flatter belly, your mind may immediately go to crunches and other core-targeting moves. But while abdominal exercises can tighten the muscles and make the abdomen look better, Dr. Petre says these moves won't actually trim down the fat around your waist. "Not all exercises are created equal when it comes to belly fat," she stresses.

Research, including a September 2019 study published in Mayo Clinic Proceedings, has found that high-intensity interval training (HIIT) is more effective in reducing abdominal fat compared to other types of training. Researchers noted that people who practiced HIIT not only shaved more inches off their waists but also lost more body fat and gained more lean muscle mass than those who performed other moderate-intensity exercise, including brisk walking and cycling.

Compared to low-fat diets, Dr. Petre maintains that lower-carb diets are better when it comes to blasting visceral fat. One important study, published August 2019 in the Journal of Hepatology, found that a lower-carbohydrate Mediterranean diet was more effective at reducing belly fat than a diet lower in fat.

Everyone needs fat in his or her diet. But the type of fat you're eating is important, too. Those following a Mediterranean diet are encouraged to avoid or limit saturated fats found in such foods as butter, lard, full-fat dairy, fatty meats, fried foods and commercial baked goods and instead stick to unsaturated fats like olive oil, avocado and nuts.

The Mediterranean diet also puts the focus on whole grains over refined carbs, which can help put the kibosh on belly fat. According to Harvard Health Publishing, these refined foods (think: white bread and rice, chips, sweets and sugary drinks) cause sharp spikes in blood sugar and elevate your triglyceride levels, which cause your body to store more fat around the waist.

Avocados are a smart choice when you're trying to lose belly fat.

Credit: Milan_Jovic/E+/GettyImages

Ilana Muhlstein, RD, dietitian and co-creator of Beachbody's 2B Mindset, is a fan of cruciferous veggies such as cabbage, arugula, cauliflower and Brussels sprouts as great belly fat-blasting fuel. "They are low in calories but high in fiber," she explains.

Eating more fiber can help you feel full on less food, which helps with weight loss in general. And eating more soluble fiber such as the kind found in many veggies but also flax seeds, oranges, beans and oats in particular may be key in reducing abdominal fat. One oft-cited study published in the February 2012 issue of Obesity followed more than 1,000 people for five years and found that each 10-gram increase in soluble fiber intake decreased belly fat accumulation by 3.7 percent.

Before you get too caught up in exactly how much and which kind of fiber you should be getting, keep in mind that there's no perfect amount to aim for instead, simply fill your plate with a variety of veggies as often as possible.

"A combined program of a low-carbohydrate and high-fiber diet with regular exercise and a de-stress plan will allow you to see a waistline again."

Research has established a link between sleep and visceral fat, Dr. Petre says. Indeed, a May 2014 study published in Obesity found that those who sleep a healthy amount of time defined by researchers as seven to eight hours a day gained significantly less visceral fat than those who slept too little or too much.

One of the culprits here is cortisol, aka the stress hormone, which your body tends to release when you're short on shut-eye. Cortisol signals your body to store more fat in your belly while also increasing your hunger and negatively affecting your metabolism.

Speaking of cortisol, research has also connected higher stress levels to more belly fat. "High cortisol levels can actually increase your visceral fat, as the hormone is known to increase the amount of fat that clings to your body and magnifies the growth of your fat cells," Dr. Petre says.

Stressful situations are nearly unavoidable in everyday life, but you do have control over your response to them, which can help mitigate the effects of cortisol on your body: Check out eight ways to beat stress-induced belly fat.

Because there are so many components involved in blasting belly fat, Dr. Petre says that motivation and commitment are key even when you don't see results right away. "A combined program of a low-carbohydrate and high-fiber diet with regular exercise and a de-stress plan will allow you to see a waistline again," she says. "You can push past your genetics and bad habits to get rid of that elastic waistband forever."

Read the original post:
How to Lose Belly Fat: 6 Things That Really Work - LIVESTRONG.COM

When should menopausal women stop taking the pill? Experts warn they may need it longer than they think

Many middle age women experiencing symptoms of the menopause wonder when they can safely stop birth control.

Now experts at the Mayo Clinic have provided clear guidance on the matter.

They warn women to heed their advice as they say birth control is often something women, perhaps in their forties or early fifties, stop worrying about a little too soon.

Indeed, research that shows 75 per cent of pregnancies in women over 40 are unplanned.

Furthermore, some pregnancy complications and risk of miscarriage go up with age.

Here, gynecologist Dr Petra Casey from the clinic addresses some of thecommon questions older women ask of their gynecologists.

What age does the menopause start?

The menopause is when a woman stops having periods and is no longer able to get pregnant naturally.

Periods usually start to become less frequent over a few months or years before they stop altogether. Sometimes they can stop suddenly.

The menopause usually occurs between 45 and 55 years of age, as a womans oestrogen levels decline. In the UK, the average age for a woman to reach the menopause is 51.

When is it safe to stop birth control?

Signs of menopause can occur up to several years before a womans final period, a transition time known as perimenopause.Once you have missed your period for a year, you are considered menopausal and may safely stop birth control.

But be warned, if you reach 11-and-a-half months of no periods, then have a period, the clock starts all over again and youre still not in menopause.

Sometimes lab tests are also performed to confirm menopause, but most women dont need them.

About 90 to 95 per cent of women will be menopausal by 55 and may stop birth control then. But if you dont want to become pregnant, using effective birth control until you are truly menopausal is very important.

What birth control is best for women over age 35 or 40?

IUDs are recommended as the most protective form of birth control

If you are at a healthy weight, dont smoke, dont have high blood pressure or history of blood clots, you can probably continue the oral contraceptive pill, patch or ring well into your 50s.

Hormonal oral contraceptives can provide a number of benefits for perimenopausal women beyond preventing pregnancy.

These include reduced hot flashes, reduced menstrual bleeding and decreased risk of ovarian and uterine cancer.

What if I want to avoid hormones?

Perimenopausal women should not use estrogen-containing contraceptives if they smoke or have a history of estrogen-dependent cancer, heart disease, high blood pressure, diabetes, or blood clots.

If you would like to avoid hormones as you transition into menopause, you can use the copper IUD, barrier methods like condoms, cervical cap, diaphragm or sponge, or have a minor surgical procedure to tie or block your fallopian tubes.

Other great options which dont contain the hormone estrogen include IUDs, implants, shots and minipills.

Some IUDs contain the hormone levonorgestrel, a kind of progestin, which helps decrease or even eliminate heavy menstrual bleeding, a common problem for women in their 40s.These types of IUDs last three to five years.

Another kind of IUD is made of copper, does not contain hormones and can last up to 10 years.They are more effective than pills in preventing pregnancy.

What if Ive had unprotected sex?

Just in case you had unprotected sex and you dont wish to become pregnant, there are also several kinds of emergency contraception.

There are morning after pills thatcontain the hormone levonorgestrel, such as Levonelle, which work by delaying ovulation or release of an egg. They do not interfere with an established pregnancy or cause a miscarriage.

It is most effective when taken within 12 hours of unprotected sex, although it can be effective for up to 72 hours after sex.

Most women will experience menopausal symptoms.

Some of these can be quite severe and have a significant impact on your everyday activities.

Common symptoms include:

Menopausal symptoms can begin months or even years before your periods stop and last around four years after your last period, although some women experience them for much longer.

Source: NHS Choices

Another option which is more effective, especially if you are heavier, is ellaOne. Ella is effective in decreasing the risk of pregnancy up to five days after unprotected sex.

A copper IUD inserted within five days of unprotected sex is the most effective option for emergency contraception but requires an appointment with a health care provider. You can keep it for birth control for up to 10 years.

Can I combine hormone replacement therapy and contraception?

You can start on menopausal hormone therapy using an estrogen patch to help manage symptoms and use one of the progestin-only birth control options for contraception and to protect the uterine lining from growing too much with the estrogen.

The progestin-containing IUD, implant, shot or minipill all work well for this. If you have had a hysterectomy, you can take estrogen alone.

Your GP can help guide you in choosing the best birth control option for you during the menopausal transition.

Go here to read the rest:
Mayo Clinic say menopausal women need the pill for longer - Stock Daily Dish

True story: when I was in high school, friends of mine would avoid taking the sugar pills included in the combination birth control pill for fear of gaining weight.

While on reflection this sounds pretty ridiculous, a Google search of the sugar content in these placebo or inactive pills (as their medically known) reveals not much.

The actual ingredients in the pills sugar tablets varies slightly depending on the manufacturer.

Essentially, each placebo pill is made up of whats known as excipients: fillers and binders that fill out the size of a tablet, provide colour, and hold the ingredients together so its convenient to consume.

According to Head of the Department of General Practice at Monash University, Professor Danielle Mazza, these usually include sucrose (sugar), calcium carbonate, magnesium stearate, glycerol, iron oxide yellow, and povidone.

There is also lactose in most tablets, but not enough lactose to bother someone who is lactose intolerant says Dr Terri Foran, sexual health physician and lecturer with the UNSW School of Women's & Children's Health, and director of Master Womens Health Medicine.

As the inactive pills contain no hormones or active ingredients, they provide no medical benefit.

The exact quantity of sugar (or any ingredient) in the placebo pills is not usually revealed by manufacturers. However, doctors say the possibility of this causing weight gain is unlikely or a complete myth.

The amount of sugar is tiny. There is not enough to cause any weight gain and skipping them will not prevent weight gain, says Dr Foran.

No, is the short answer.

People on the pill are able to manipulate their cycle in a number of ways, such as by running pill packets of the same type back-to-back so they are consistently taking the active pills only.

Those who choose to have the hormone-free break in their cycle, can choose to not take any tablet at all on these days. They may alternatively decide to take the inactive tablets for a shorter period than their packet suggests.

In Australia, women have been running pill packs together forever and it is perfectly safe to do so, says Dr Foran. In the US they have a pill with no placebo pills at all.

The UKs Faculty of Sexual and Reproductive Healthcare recently updated its official guidance to say there is no health benefit from the seven-day hormone-free interval. In Australia, Family Planning NSW associate medical director Dr Clare Boerma says this remains an off-packet but widely accepted practice.

No. Dr Boerma says it is medically unnecessary to have the withdrawal bleed brought on by a break in active pills.

I hear in my clinic lots of myths that women have about the need to have this monthly break from hormones, or some women get the idea that you're going to have a buildup of lots of blood and clots on the inside if you don't let it out, Dr Boerma says.

Actually, the pill works just in the lining of your womb really well, so there's not something actually building up to be released, so to speak.

It's not actually a period people think of it as periods but the pill is stopping you ovulating so it's a withdrawal bleed from the drop of hormone as opposed to relating to a natural cycle of hormones in your body. So it's a fake period.

The pill could be more effective when the placebo pills are skipped altogether, as this allows less room for user error.

Good question. Theres a few reasons:

1. To avoid breakthrough bleeding, which is more likely to occur when the active tablets are consistently taken with no break.

2. To assure users they arent pregnant.

3. To keep users in the routine of taking a tablet a day, should they choose to have a withdrawal bleed.

4. To mimic the natural cycle.

5. To appease the Catholic Church.

Whats the Catholic Church got to do with it?

It was recently claimed that one of the pills Catholic co-founders invented the withdrawal bleed in an attempt to persuade the Vatican to accept the new form of contraception, as an extension of the natural menstrual cycle

While this attempt was unsuccessful, both Dr Foran and Dr Boerma say this was a likely reason for the withdrawal bleeds inclusion, combined with the other reasons for the hormone-free break such as to mimic the natural menstrual cycle.

Disclaimer: This article contains general information only. It is not intended to replace the advice provided by your own doctor or medical or health professional.

See more here:
What's really in those 'sugar' birth control pills - SBS News

Ness Berminghams latest venture brings throwbacks to some of his earliest work in biopharma. Part of his PhD work at Imperial College London revolved around triplet repeat disorders, a group of 40 or so genetic diseases characterized by the repetition and expansion of specific trinucleotide sequences. During his early years at Atlas Venture way before he became known as a co-founder of pioneering CRISPR player Intellia he helped create a biotech, Prestwick Pharmaceuticals, that created a Huntingtons drug dubbed tetrabenazine.

Back then and until very recently even though Huntingtons and other diseases such as spinocerebellar ataxia and myotonic dystrophy fell under the same umbrella, they were construed as separate afflictions. A potentially unifying theory, as it turned out, lay in one question: Why dont patients born with the same repeats always begin to see symptoms at the same age?

For quite some time people had known that there are these genetic modifiers that really seem to profoundly impact these diseases and the onset and progression of these diseases, Bermingham told Endpoints News.

Triplet Therapeutics, which is doing the rounds today with $59 million in launch cash from Atlas, MPM Capital and Pfizer Ventures, believes the key to that mechanism is the DNA damage response pathway.

The DNA damage response pathway, or DDR, is a crucial way for cells to repair genetic material. But in patients with repeat expansion disorders, when their DDR machine goes in to fix the kinks during DNA replication, they also insert multiple repeating sequences in turn blowing up the size of the DNA so much that its more prone to damage, creating a snowball effect, according to Bermingham.

Out of about 100 genes involved in the DDR pathway, Triplet has identified a couple key drivers that they can target to stop the insertion of repeats, thereby holding the disease at bay.

That has allowed to shift their thinking from a disease standpoint to a tissue standpoint, Bermingham said, and the first tissue they will go after is the brain: Huntingtons, multiple subtypes of spinocerebellar ataxia, dentatorubralpallidoluysian atrophy, myotonic dystrophy, and so on.

As you move from tissue to tissue, it opens up different drugs of different formulations that hit the same target, he said.

Unlike at Korro Bio, the RNA editing outfit Bermingham has recently unveiled as executive chairman, Triplet is not looking to new tools. Rather, the goal is to home in on a fundamental driver of disease upstream of what rivals like Roche/Ionis and Wave are knocking out in Huntingtons.

The candidates they are now testing in non-human primates for CNS disorders are antisense oligonucleotides, but for other tissues such as muscles, the eye or even the kidney, they also plan to use small interfering RNA. These tools were chosen as they provide more specific targeting and less safety issues than, say, small molecules, Bermingham said.

The CEO added that using ASO and siRNA has allowed his team of 29 to move quickly, ready to enter the clinic within two years the runway that the Series A (also featuring Invus, Partners Innovation Fund and Alexandria Venture Investments) is providing. In the process hes looking to grow the company to somewhere between 45 to 60.

Currently helping Bermingham run the operations are some seasoned execs in the space: Irina Antonijevic, SVP of development, previously led translational medicine and early development at Wave; Brian Bettencourt, SVP of computational biology & statistics, specialized in modeling and design of oligonucleotide and mRNA at Translate Bio; David Morrissey, SVP of technology, and Peter Blalek, head of translational sciences, are both old colleagues from Intellia; Head of pharmacology Pei Ge led the Huntingtons program at Alnylam before moving to Ironwood; Eric Sullivan, CFO, was formerly of Gemini Therapeutics and bluebird bio; and Jeffrey Cerio, general counsel, has served at Moderna.

Shinichiro Fuse of MPM and Laszlo Kiss of Pfizer Ventures are joining the board, chaired by Atlas partner Jean-Franois Formela, alongside Douglas Kerr, chief development officer at Generation Bio. Then theres the scientific advisory board comprising three academic experts, including Vanessa Wheeler at Massachusetts General Hospital, who happened to be a PhD mate of Berminghams.

Ramping up would mean spending the majority of his time with Triplet at the new Kendall Square offices they are moving into in January, slightly detached from Atlas which he rejoined as venture partner less than two years ago in the wake of his exit from the helm of Intellia.

Its my intent to stay here and see this company through, he said. Im trained as a human geneticist originally, and then further specialized down to molecular biology. So this is absolutely in my sweet spot.

Read more from the original source:
What unifies Huntington's, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham's new startup looks to drug that - Endpoints News

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global stem cell therapy market was valued at US$ 7,313.6 million in 2018, and is expected to exhibit a CAGR of 21.1% over the forecast period (2019-2027).

Key Trends and Analysis of the Stem cell therapy Market:

Key trends in market are increasing incidence of cancer and osteoporosis, rising number of research and development activities for product development, and adoption of growth strategies such as acquisitions, collaborations, product launches by the market players.

Key players are focused on launches of production facility for offering better stem cell therapy in the potential market. For instance, in January 2019, FUJIFILM Cellular Dynamics, Inc., a subsidiary of FUJIFILM Corporation, announced to invest around US$ 21 Mn for building new cGMP-compliant production facility, in order to enhance production capacity of induced pluripotent stem (iPS) cell for the development of cell therapy and regenerative medicine products. The new facility is expected to begin its operations by March 2020.

Request your Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/2848

Market players are adopting inorganic growth strategies such as acquisitions and collaborations, in order to enhance their offerings in the potential market. For instance, in August 2019, Bayer AG acquired BlueRock Therapeutics, a company developing cell therapies based on induced pluripotent stem cell (iPSC) platform. This acquisition is expected to strengthen Bayers market position in the stem cell therapy market.

Furthermore, increasing research and development activities of stem cells by research organizations to provide efficient treatment options to patients suffering from various chronic diseases is expected to drive growth of the stem cell therapy market over the forecast period. For instance, in January, 2019, the Center for Beta Cell Therapy in Diabetes and ViaCyte, Inc. initiated a trial of human stem cell-derived product candidates in type 1 diabetes patients in Europe.

However, high cost of preservation of stem cells and other factors is expected to hamper growth of stem cell therapy market over the forecast period. High cost of stem cell storage is a factor that is expected to hinder growth of the market. For instance, according to the Meredith Corporation, a private bank generally charges US$ 1,200 to US$ 2,300 to collect cord blood at the time of delivery, with annual storage fees of US$ 100 to US$ 300 each year. Thus, high cost associated with stem cell storage combined with high production cost are expected to hinder growth of the market, especially in emerging economies.

Key Market Takeaways:

Buy this Report (Single User License) @ https://www.coherentmarketinsights.com/insight/buy-now/2848

Market Segmentations:

Read the rest here:
Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 Coherent Market Insights - Business Wire

Earlier this year, the US Food and Drug Administration approved the most expensive drug ever to hit the market, a gene therapy for spinal muscular atrophy. SMA is a neuromuscular disorder that, in severe cases, can lead to infant death. The genetic correction is currently used to treat affected newborns, but as symptoms for some types of SMA may appear before birth, an earlier treatment would be potentially more effective.

In a study published December 4 in Molecular Therapy, researchers were able to fix a mutation in the survival motor neuron 1 (SMN1) genewhich causes SMA in humansin mice modelling the disease, while they were still inside their mothers uterus. The treated mice lived longer and had fewer symptoms than untreated animals.

Tippi MacKenzie, a fetal and pediatric surgeon at the University of California, San Francisco, who did not participate in this study, says it is an important paper because it is the first time fetal gene therapy has succeeded in SMA mice. Before you even think about doing something in patients, you have to first do it in the disease model of the mouse . . . so this group has supplied a very important piece to the literature, she adds.

SMN1encodes an essential protein for the maintenance of motor neurons, which are nerve cells in the brain and spinal cord responsible for controlling muscle movement. The result in children with mutations in the gene is the loss of motor neurons, leading to muscle weakness and associated complications. SMA affects one out of every 6,000 to 10,000 babies.

Correcting the SMN1 sequence is a potentially efficient treatment for those born with SMA. Zolgensma, the recently approved medication for this disorder, consists of an intravenous administration of an adeno-associated virus that ferries a functional copy of the SMN1 gene to the brain.

To see if the same fix could be accomplished before birth, the research team tested two different injection methods: one into the placenta (intraplacental or IP) and the other into one of the brain lateral ventricles (intracerebroventricular or ICV). The latter proved to be more effective. By injecting the viral vector into the fetuss brain, the virus will go directly into the cerebrospinal fluid, and it will transduce motor neurons in the spinal cord with a very high efficiency, compared to the IP [injection], says Afrooz Rashnonejad. who participated in this study while working at Ege University in Izmir, Turkey, but has recently moved to Nationwide Childrens Hospital in Columbus, Ohio.

Rashnonejad and her colleagues then monitored the injected mice that were carried to term. Those treated with the vector carrying a functional copy of SMN1 lived a median lifespan of 63 or 105 days (depending on the type of cassette carrying the gene), much longer than untreated SMA mice, which did not survive more than 14 days, but still less than wildtype pups, which had a median lifespan of 405 days. The treated mice were also heavier than untreated mice, but smaller than healthy mice.

The investigators also observed differences at the cellular and molecular levels. SMN protein levels were completely recovered in the brain and spinal cord, and the number of motor neurons was higher in treated animals.

I was just very impressed by what theyve done, says Simon Waddington, a gene therapy researcher at University College London who did not participate in this work, but was one of the reviewers of the paper. He adds that he and other colleagues had previously tried fetal gene therapy on SMA mice, but had failed as it is a technically difficult experiment. So it was really nice to see this group actually did a really good job.

This is the first time viral vectors have been used to successfully boost gene expression in SMA mice before birth. Interventions to edit the genome in utero have been previously used in mice that model other severe genetic diseases. Last year, for instance, Waddington and colleagues used fetal gene therapy to treat mice affected by Gaucher disease, a neurodegenerative disorder that can be fatal for newborns. Other successful attempts include intrauterine gene editing for mice affected by -thalassemia, an inherited blood disorder, and mice suffering a monogenic lung disease that normally results in newborn death.

MacKenzie says that, in a recent national meeting on in utero gene therapy, it was discussed how to move forward with a clinical application to the FDA. We are definitively moving towards that direction, but we dont have a particular application yet, because its still not clear which disease should be the first.

SMA makes a lot of sense because its so severe, MacKenzie adds. But at the same time, the results that are coming out at conferences, she observes, suggest that newborn babies receiving Zolgensma are doing pretty well, better than anybody could have imagined. So its not clear that you have to go before birth. A good candidate, she explains, would be a very rare type of SMA, where the baby dies before birth.

Waddington says that researchers might have to wait for neonatal gene therapy to become standard for certain diseases before using fetal gene therapy in humans. Once we actually understand how efficient this is, and if we come to the point where we discover that the earlier that you go the more effective it is . . . in a human setting, then we may be able to do fetal gene therapy. I think that we are looking at more than five years away before thats even likely to happen, he hypothesizes.

A. Rashnonejad et al., Fetal gene therapy using a single injection of recombinant AAV9 rescued SMA phenotype in mice,Molecular Therapy, 27:212333, 2019.

Alejandra Manjarrez is a freelance science journalist. Email her atalejandra.manjarrezc@gmail.com.

See the article here:
Fetal Gene Therapy Helps Mice with Spinal Muscular Atrophy - The Scientist

Abstract / Synopsis:

Two anti-VEGF gene therapies are being investigated in clinical trials of patients with exudative age-related macular degeneration. Initial efficacy and safety results are encouraging.

Anti-VEGF gene therapy for exudative age-related macular degeneration (AMD) has transformative potential for reducing treatment burden and improving patient outcomes, according to Szilrd Kiss, MD.

Two investigational anti-VEGF gene therapies are currently being investigated in clinical trialsRGX-314 (Regenxbio) and ADVM-022 (Adverum). Dr. Kiss described the two technologies and reviewed some preliminary clinical trial results that support their promise for providing sustained benefit with a single injection.

Considering the treatment burden of anti-VEGF therapy for other ocular diseases, we can imagine that exudative AMD is just the first indication that will be targeted for anti-VEGF gene therapy, said Dr. Kiss, chief, Retina Service, associate professor of ophthalmology, and associate dean at Weill Cornell Medical College, New York, NY.

RGX-314 delivers a gene for an anti-VEGF fab protein that is similar to ranibizumab. It uses adeno-associated virus-8 (AAV8) as a vector and is administered in the operating room as a subretinal injection.

AAV is the most common viral vector carrier used for gene therapy. Different AAV serotypes have different tissue selectivity, Dr. Kiss explained. AAV8 is a wild type AAV that has the propensity for greater transfection of retinal cells compared with AAV2 following subretinal gene therapy delivery.

RELATED:AAO 2019: Encouraging results revealed from early trial of subretinal gene therapy for wet AMD

Disclosures:

Szilrd Kiss, MDe: [emailprotected]This article was adapted from Dr. Kiss presentation at the 2019 meeting of the American Academy of Ophthalmology. Dr. Kiss is a consultant to RegenxBio and Spark Therapeutics and is a consultant and equity owner in Adverum.

Read more from the original source:
Research targets gene therapy for exudative AMD patients - Modern Retina

A vector is a microscopic carrier of pieces of DNA. It is used to deliver healthy copies of genes to tissues and organs within patients or deliver the ability to correct the genetic errors. While the technology is moving rapidly, production of vectors is not.

NSW, and in particular the Westmead Precinct, is already at the forefront of international gene therapy research. The aim of this project is to speed up research and translate it into cures for serious genetic diseases affecting children.

The facility will produce vectors to treat illnesses impacting everything from those with life-threatening liver disease to children going blind. Currently the vectors need to imported and its extremely costly to get them to Australia.

Professor Ian Alexander, Head of the Gene Therapy Research Unit at Childrens Medical Research Institute, senior clinician at The Childrens Hospital at Westmead and Professor of Paediatric and Molecular Medicine at the University of Sydney, said the manufacturing facility would be a boost to translation of academic research in NSW.

We see it as the beginning of something much greater, Professor Alexander said.

It is about moving technology into the clinic, which, in future, will benefit many more patients by offering new and better treatment opportunities. This technology could translate into saving the lives of infants with life-threatening conditions.

Dr Leszek Lisowski heads the Translational Vectorology Group at CMRI and is Conjoint Senior Lecturer at the University of Sydney. His team will play a key role in the new facility, through training of staff and developing the manufacturing processes that will underpin operations. In addition, his team specialises in the development of novel vectors optimised for clinical applications targeting liver, eye and many other clinically important organs and tissues.

Dr Lisowski said that this new facility will allow Australian investigators to get around the "bottleneck" of getting vectors from overseas.

The biggest bottleneck that slows down translation of gene therapy tools to the patient is a global lack of vector manufacturing capacity, which significantly extends the timeline and increases the cost of translational studies," he said.

This facility will give Australian researchers prioritised and cost-effective access to clinical gene therapy reagents and will facilitate translation of a large number of exciting preclinical programs from bench to bedside.

The team is excited by this vital investment and looks forward to partnering with government and other funders to enable the facility to achieve its full potential.

The Westmead Precinct is one of the largest health, education, research and training precincts in Australia and a key provider of jobs for the greater Parramatta and western Sydney region. Spanning 75 hectares, the Precinct includes four hospitals, four world-leading medical research institutes, two multidisciplinary university campuses and the largest research-intensive pathology service in NSW.

The University of Sydney has long been a proud partner of the Precinct and is in negotiations about developing a second major campus in the area. By 2050, that campus will include 25,000 students; 1000 staff and researchers; generate $21.7 billion for the NSW economy and support up to 20,000 jobs.

University of Sydney Vice-Chancellor and Principal Dr Michael Spence said that as part of our collaborative work in building a western Sydney global centre of excellence, Precinct partners are growing Australias advanced manufacturing capability.

These developments will strengthen crucial collaborations in the Precinct from R&D and design to distribution in areas such as prevention and wellbeing, biomedical engineering, AI and personalised medicine, Dr Spence said.

Faculty of Medicine and Health Executive Dean Professor Robyn Ward said: This technology will scale up gene therapy using viral vectors from single-condition, life changing successes, for example in spinal muscle atrophy, to a national service.

We are so proud of this leadership at the Westmead Precinct and with our health partners. It is a whole-of-lifespan, true bench-to-clinic approach."

Go here to read the rest:
Westmead advanced manufacturing to transform lives - News - The University of Sydney

Recent research on longevity is making the idea of an elixir of life sound increasingly plausible. But a startup thats started selling a $1 million anti-aging treatment is most likely jumping the gun.

Libella Gene Therapeutics says it will administer volunteers with a gene therapy that it claims can reverse aging by up to 20 years, according to OneZero. Despite the fact that this is the first human trial of the treatment, the company is charging volunteers $1m to take part. In an effort to side-step the FDA, the trial will take place in Colombia.

The therapy will attempt to repair peoples telomeres, the caps on the end of our chromosomes that shorten as people get older. Its long been thought that they play a role in aging, and efforts to extend telomeres in mice have shown that it can delay the signs of getting older and increase healthy lifespan, though its yet to be tested in humans.

Libellas therapy will use viruses to deliver a gene called TERT, which codes for an enzyme called telomerase that re-builds teleomeres, to the patients cells.

Experts told MIT Tech Review that the trial is unethical, poorly designed, and presents serious risks to participants, including the danger of activating dormant cancerous cells. But its also still unclear whether the trial will go ahead, because the company has made previous announcements before without following through.

Whether or not it does, though, medical treatments to head off the slow march towards death are likely to become increasingly common. A growing body of research suggests that aging is an entirely preventable condition and that there may be a variety of ways to treat it, from lifestyle changes to dramatic genetic interventions.

In 2017, scientists showed that using drugs to reprogram epigenetic markerschemical attachments responsible for regulating the genomein mice extended their lifespan by 30 percent. And in 2018, another team showed that using a combination of drugs to kill senescent cellszombie cells that leak harmful chemicals, damaging nearby tissuecould boost the longevity of mice by 36 percent.

Famous geneticist George Church has even launched a startup called Rejuvenate Bio that will use proprietary genetic treatments to prolong the lives of dogs, though he has admitted the ultimate goal is to extend its technology to humans. Last month Churchs group at Harvard also showed that using gene therapies to tackle three age-related diseases at once was effective in mice.

The first anti-aging treatments for people are already starting to appear as well. CEO of longevity company BioViva Elizabeth Parrish injected herself with a gene therapy similar to Libellas back in 2015, and the company has claimed it was successful in lengthening her telomeres, though results were never published.

Earlier this year a study on humans found that a cocktail of drugs could reset the epigenetic clock, epigenetic markers used to measure a persons biological age. The participants also showed signs of a rejuvenated immune system.

And more controversially, the FDA recently had to put out a public service announcement telling people to stop injecting blood plasma from younger people. The idea is built upon recent research that showed a rejuvenating effect in mice, but most experts say its far too early to apply it to humans.

Whether the FDA will be able to keep on top of this burgeoning and highly lucrative market remains to be seen, but given the potential side effects of many of these treatments, it should be a priority.

We also need to have a more in-depth conversation about what these longevity therapies mean for society. Assuming this new trial is effective, what does it mean if only those with $1m to spare get to extend their lives? If treating aging becomes trivial, how is that going to change the nature of our communities? These are questions that may become increasingly relevant in the coming decades.

Image Credit: Shutterstock.com

The rest is here:
A New Anti-Aging Therapy Is Starting Its First Human Trialand It Costs $1 Million - Singularity Hub

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time. During the event, Sangamo executives and scientists plan to provide updates across the Companys clinical and preclinical pipeline, as well as an overview of manufacturing capabilities to support clinical and commercial supply. A live webcast link will be available on the Events and Presentations page of the Sangamo website

The talent, R&D capabilities, manufacturing expertise, and operations infrastructure we have brought to Sangamo have enabled us to advance a genomic medicine pipeline that spans multiple therapeutic areas and now also extends into late-stage development, said Sandy Macrae, CEO of Sangamo. As we make progress in clinical development, we gain insights into the use of our technology and are applying those insights as we advance new programs, such as the gene therapy for PKU and the genome regulation candidates for CNS diseases we are announcing today.

Macrae continued: We will continue to pursue a dual approach of retaining certain programs for our proprietary pipeline while also establishing pharmaceutical partnerships to gain access to therapeutic area expertise and financial, operational, and commercial resources. Strategic collaborations will be a particularly important consideration as we advance programs for diseases affecting large patient populations.

R&D Day updates on clinical and preclinical pipeline programs:

Gene therapy product candidates for hemophilia A, Fabry disease, and PKU

SB-525 is a gene therapy product candidate for hemophilia A being developed by Sangamo and Pfizer under a global development and commercialization collaboration agreement. The transfer of the SB-525 IND to Pfizer is substantially completed. Pfizer is advancing SB-525 into a Phase 3 registrational study in 2020 and has recently begun enrolling patients into a Phase 3 lead-in study.

At R&D Day, Sangamo executives are presenting data from the SB-525 program which were recently announced at the American Society of Hematology (ASH) annual meeting.

The cassette engineering, AAV engineering and manufacturing expertise which Sangamo used in the development of SB-525 are also being applied to the ST-920 Fabry disease program, which is being evaluated in a Phase 1/2 clinical trial, as well as to the newly announced ST-101 gene therapy program for PKU, which is being evaluated in preclinical studies with a planned IND submission in 2021.

Engineered ex vivo cell therapy candidates for beta thalassemia, kidney transplantation, and preclinical research in multiple sclerosis (MS)

Sangamo is providing an overview of the Companys diversified cell therapy pipeline this morning. Cell therapy incorporates Sangamos experience and core strengths, including cell culture and engineering, gene editing, and AAV manufacturing. At R&D Day, Sangamo scientists today are reviewing the early data presented this month at ASH from the ST-400 beta thalassemia ex vivo gene-edited cell therapy program, which is being developed in partnership with Sanofi.

Sangamo is also providing updates on the companys CAR-TREG clinical and preclinical programs. CAR-TREGS are regulatory T cells equipped with a chimeric antigen receptor. Sangamo is the pioneer in CAR-TREGS, which may have the potential to treat inflammatory and autoimmune diseases. TX200 is being evaluated in the STEADFAST study, the first ever clinical trial evaluating a CAR-TREG cell therapy. Tx200 is being developed for the prevention of immune-mediated organ rejection in patients who have received a kidney transplant, a significant unmet medical need. Results from this trial will provide data on safety and proof of mechanism, building a critical understanding of CAR-TREGS in patients, and may provide a gateway to autoimmune indications such as Crohns disease and multiple sclerosis (MS). Sangamo is also presenting preclinical murine data demonstrating that CAR-TREGS accumulate and proliferate in the CNS and reduce a marker of MS.

In vivo genome editing optimization

Clinical data presented earlier this year provided evidence that Sangamo had successfully edited the genome of patients with mucopolysaccharidosis type II (MPS II) but also suggested that the zinc finger nuclease in vivo gene editing reagents were under-dosed using first-generation technology. Sangamo has identified potential improvements that may enhance the potency of in vivo genome editing, including increasing total AAV vector dose, co-packaging both ZFNs in one AAV vector, and engineering second-generation AAVs, ZFNs, and donor transgenes.

Genome regulation pipeline candidates targeting neurodegenerative diseases including Alzheimers and Parkinsons

Sangamo scientists today are presenting data demonstrating that the companys engineered zinc finger protein transcription factors (ZFP-TFs) specifically and powerfully repress key genes involved in brain diseases including Alzheimers, Parkinsons, Huntingtons, ALS, and Prion diseases. Sangamo is advancing its first two genome regulation programs toward clinical development:

Sangamo scientists are also presenting data demonstrating progress in the development of new AAV serotypes for use in CNS diseases.

Manufacturing capabilities and strategy

Sangamo is nearing completion of its buildout of a GMP manufacturing facility at the new Company headquarters in Brisbane, CA. This facility is expected to become operational in 2020 and to provide clinical and commercial scale manufacturing capacity for cell and gene therapy programs. The Company has also initiated the buildout of a cell therapy manufacturing facility in Valbonne, France. Sangamos manufacturing strategy includes in-house capabilities as well as the use of contract manufacturing organizations, including a long-established relationship with Thermo Fisher Scientific for clinical and large-scale commercial AAV manufacturing capacity.

R&D Day webcast

A live webcast of the R&D Day, including audio and slides, will be available on the Events and Presentations page of the Sangamo website today at 8am Eastern Time. A replay of the event will be archived on the website.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.

Sangamo Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of United States securities law. These forward-looking statements include, but are not limited to, the therapeutic potential of Sangamos product candidates; the design of clinical trials and expected timing for milestones, such as enrollment and presentation of data, the expected timing of release of additional data, plans to initiate additional studies for product candidates and timing and design of these studies; the expected benefits of Sangamos collaborations; the anticipated capabilities of Sangamos technologies; the research and development of novel gene-based therapies and the application of Sangamos ZFP technology platform to specific human diseases; successful manufacturing of Sangamos product candidates; the potential of Sangamos genome editing technology to safely treat genetic diseases; the potential for ZFNs to be effectively designed to treat diseases through genome editing; the potential for cell therapies to effectively treat diseases; and other statements that are not historical fact. These statements are based upon Sangamos current expectations and speak only as of the date hereof. Sangamos actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to dependence on the success of clinical trials; the uncertain regulatory approval process; the costly research and development process, including the uncertain timing of clinical trials; whether interim, preliminary or initial data from ongoing clinical trials will be representative of the final results from such clinical trials; whether the final results from ongoing clinical trials will validate and support the safety and efficacy of product candidates; the risk that clinical trial data are subject to differing interpretations by regulatory authorities; Sangamos limited experience in conducting later stage clinical trials and the potential inability of Sangamo and its partners to advance product candidates into registrational studies; Sangamos reliance on itself, partners and other third-parties to meet clinical and manufacturing obligations; Sangamos ability to maintain strategic partnerships; competing drugs and product candidates that may be superior to Sangamos product candidates; and the potential for technological developments by Sangamo's competitors that will obviate Sangamo's gene therapy technology. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamos operations. This presentation concerns investigational drugs that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by any regulatory agency. They are currently limited to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated. Any discussions of safety or efficacy are only in reference to the specific results presented here and may not be indicative of an ultimate finding of safety or efficacy by regulatory agencies. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 1, 2019 and Sangamo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 that it filed on or about November 6, 2019. Except as required by law, we assume no obligation, and we disclaim any intent, to update these statements to reflect actual results.

See the original post:
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day - Business Wire

CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients,today announced ithas entered into an exclusive license with Oregon Health & Science University (OHSU) to intellectual property rights owned by OHSU while also extending a sponsored research agreement (SRA) to explore methods for enhancing selective advantage of edited hepatocytes using pharmacological agents with the laboratory ofMarkusGrompe, M.D.,professor at OHSU. The initial phase of the research program provided proof-of-principle of enhanced selective advantage for cells edited by GeneRide in pilot murine experiments. This extension phase will focus on translating the enhancement strategy to non-human primates, a critical step before clinical translation to future GeneRide candidates and other technologies. GeneRide is LogicBios proprietarypromoterless, nuclease-free genome editing technology,whichis designed to provide a stable therapeutic effect by harnessing homologous recombination to precisely integrate corrective genes into a patients genome and leveraging endogenous promoters to drive gene expression.

LogicBiois currently working primarily in disorders where patients can benefit substantially even when only a modest percentage of their cells are modified and begin expressing the corrective transgene introduced by GeneRide. The Company has found, however, that in some genetic contexts, integrating the transgene gives hepatocytes a naturally-occurring selective advantage over cells that have not been modified. Over time, the percentage of modified cells expressing that transgene rises, potentially leading to more robust patient benefits. This wasobserved inan experimentin which a murine GeneRide construct was introduced into mice with and without a functioning copy of theMutgene (deficient in the pediatric disease methylmalonic acidemia) in the liver. The initial GeneRide integration frequency was less than 1% in both sets of mice. Over time, this percentage remained stable in heterozygous mice that naturally expressMutin the liver (Mut+/- in liver). However, the share of cells expressing Mut increased to approximately 25% over more than a year in the mice genetically deficient in liverMut(Mut-/- in liver). This selective advantage could be attributed to improvements in mitochondrial function as a result ofMutexpression and restoration of the deficient essential metabolic pathway.These data were presented at the 2019 American Society of Gene & Cell Therapy Annual Meeting and can be found on the LogicBio website at the following link: https://investor.logicbio.com/events-and-presentations/presentations.

The goal of the expanded SRA with OHSUis to refine the pharmacological approachto providing a selective advantage to gene modified cells even when the transgene does not naturally confer a selection advantage at the cellular level. One such method involves adding an element to a GeneRide construct that gives cells incorporating that element a selective advantage when patients are treated with an external approved pharmacological agent.This research could enable expansion of the GeneRide platform to address genetic disorders in which clinical benefit emerges only after a higher percentage of cells are modified and begin expressing the corrective transgene.

We are excited to explore novel methods for enriching the number of cells expressing the therapeutic gene, said Dr. Grompe. Such methods could improve the likelihood that patients derive long-term therapeutic benefit from a single treatment. They could also expand the range of serious genetic disorders we can address with GeneRide.

Dr. Grompes lab studies monogenic disorders, particularly metabolic liver diseases affecting children. He has focused extensively on the use of in vivo selection to enhance cell and gene therapies. Dr. Grompe received the E. Mead Johnson Award for research excellence from the Society for Pediatric Research in 2002. He retains an active clinical practice, focused on metabolic disease.

About LogicBio TherapeuticsLogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free andpromoterlessapproach by relying on the native process of homologous recombination to drive potential lifelong expression. Headquartered in Cambridge, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

For more information, please visitwww.logicbio.com.

Forward Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. These are not statements of historical facts and are based on managements beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Companys plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Companys current and future research and development activities and preclinical studies and potential future clinical trials. These risks are discussed in the Companys filings with the U.S. Securities and Exchange Commission (SEC), including, without limitation, the Companys Annual Report on Form 10-K filed on April 1, 2019 with the SEC, and the Companys subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Contacts:

Brian LuqueAssociate Director, Investor Relationsbluque@logicbio.com951-206-1200

Stephanie SimonTen Bridge Communicationsstephanie@tenbridgecommunications.com617-581-9333

Read more:
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of...

One of the best things about being on the University of WisconsinMadison campus is the opportunity to learn from its passionate scientists and students. Covering the research stories of the institution keeps us busy, but it also provides the opportunity to have some fun (but dont tell the bosses!). While we believe that every story we do is important, here are some of the ones that taught us the most in 2019.

Chris Barncard, Eric Hamilton and Kelly April Tyrrell, Research Communications

Earths last magnetic field reversal took far longer than once thought

Some scientists think were living through the beginning of the next reversal of Earths magnetic field, which would affect our heavily electronic world in bizarre ways. Thankfully, new research from geoscientist Brad Singer found evidence that the last time Earths field reversed, it took about 22,000 years to complete. Thats several times longer than researchers previously thought and means that humanity would likely have generations to adapt to the next lengthy period of magnetic instability.

Genes behind lager yeasts cold- and sugar-loving success revealed

Lager beer is cold, crisp, dry and worth hundreds of billions of dollars. Genetics professor Chris Todd Hittinger and his lab recently discovered that lager yeast tolerates the cold because it inherited the power-generating portion of the cell from its cold-loving ancestor. And they figured out how this hybrid could have evolved the ability to digest all the sugars in wort to ferment a dry, crisp beer. Together, these two traits helped lager yeast and beer take over the world.

Memorial Union steam whistle sets rhythm of summer evenings and saves lives

To Terrace-goers, the steam whistle on Helen C. White Hall might just seem like a quaint way to herald another sunset. But to university and public boaters alike, its true mission is clear: keeping everyone on Lake Mendota safe enough to head out another day. UWPD Lake Rescue and Safety and the Hoofer Sailing Club collaborate to train sailors, monitor lake conditions and blow the whistle when approaching storms threaten boaters, ultimately saving lives. Thanks, whistle.

Reddit competes to visualize Madisons prized Lake Mendota ice data

For 166 years, university and state scientists have carefully tracked Lake Mendotas annual freeze and thaw. That trove of data was just what Reddit was looking for. The DataIsBeautiful subreddit competed to find the best way to visualize this long, icy record. As each graphic, animation and chart revealed, Lake Mendota has lost about a months worth of ice since record-keeping started as the result of a warming climate. That adds up to big changes for Madisons ice fishers and cross-country skiers and to the watery world beneath their feet.

Ancient poop helps show climate change contributed to fall of Cahokia

Nearly 1,000 years ago, the ancient city of Cahokia, near present-day St. Louis, was the most sophisticated prehistoric settlement north of Mexico. But then, the Mississippi River began to flood, and Cahokias population rapidly declined. Researchers at UWMadison and California State University, Long Beach found evidence using remnants of human poop and layers of sediment deposited in a nearby lake to suggest climate change contributed to Cahokias fall. Cultures can be very resilient in the face of climate change but resilience doesnt necessarily mean there is no change, says UWMadison anthropology professor Sissel Schroeder.

Fear of more dangerous second Zika, dengue infections unfounded in monkeys

Zika virus, already connected to heartbreaking consequences for newborns in recent epidemics in the Americas, was cause for additional concern among public health officials because it is so closely related to dengue virus which is dangerous enough in an initial infection, but can be even more life-threatening during a second infection. This year, UWMadisons Zika virus researchers allayed some fears that the viruses would make each other more dangerous by showing that, in monkeys, an earlier infection with one of the viral cousins does not make a later infection with the other more virulent.

Study confirms horseshoe crabs are really relatives of spiders, scorpions

When is a crab not actually crab? When its a horseshoe crab. These hard-shelled, blue-blooded creatures belong, it turns out, to the spiders and the scorpions. UWMadison evolutionary biologists Prashant Sharma and Jess Ballesteros subjected the genomes of horseshoes crabs, which have existed on Earth for 450 million years, to intense computational scrutiny and found they should live on the arachnid family tree. They are part of a lineage that makes them among the most successful animals on the planet.

Tiny capsules packed with gene-editing tools offer alternative to viral delivery of gene therapy

Gene therapy using chemical tools to edit a patients genetic code for inherited diseases, some cancers, and even stubborn viral infections is most often delivered using engineered viruses, but those viruses are hard to steer to specific cells within the body and can cause trouble by exciting the immune system. UWMadison biomedical engineers have created an alternative to viral delivery, loading tiny synthetic capsules with gene-editing tools and coating the shell with molecules that help them zero in on their therapeutic targets.

With fire, warming and drought, Yellowstone forests could be grassland by mid-century

Yellowstone National Park may be at a tipping point. Its forests are adapted for periodic fires, but large wildfires that once blazed the landscape every 100-to-300 years are now sweeping through much more frequently as the climate warms and drought conditions increase. UWMadison ecologist Monica Turner has studied the forests of Yellowstone for three decades and her work suggests forests may not be able to regenerate quickly enough. By the middle of this century, some of them may become grassland.

Lessons of conventional imaging let scientists see around corners

By playing the angles, UWMadison researchers are developing cameras that can see around corners. Led by Andreas Velten, a professor of biostatistics and medical informatics, the scientists can bounce thousands of pulses of laser light off a wall or other surface into an unseen space and collect the scattered photons that ricochet back to their sensors. Using math to reconstruct the path of the returning light, they can piece together a picture of the hidden space as seen from the perspective of their reflecting surface.

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

See more here:
2019's most memorable research stories - University of Wisconsin-Madison

IOWA CITY A University of Iowa clinician and neuroscientist has received an $18 million grant to continue a decade-long study on how a potential treatment for Huntingtons disease may affect childrens brain development.

Dr. Peg Nopoulos, chairwoman of the University of Iowa department of psychiatry, was awarded a five-year grant by the National Institution of Neurological Disorders and Strokes, part of the U.S. Institutes of Health.

These are really high-in-the-sky questions, she said. Were just boots on the ground, trying to understand how this affects children at risk for Huntingtons disease.

Huntingtons disease is a fatal genetic disorder that causes the progressive breakdown of nerve cells, diminishing thinking skills and emotions and disrupting fine motor function. If a parent has Huntingtons disease, there is a 50 percent chance her or his child will develop the same disease.

There is no cure for Huntingtons, but an emerging gene therapy in clinical trials has presented promising findings for slowing its progression, Nopoulos said. The gene therapy has been given only to individuals who have Huntingtons disease in an attempt to slow the progressive breakdown.

Nopoulos said the next step is to give the therapy to individuals before the genetic disorder takes effect, to test whether it could prevent it altogether.

However, she said this possibility presents a key question as the gene that causes the disease also is important for the growth and development of an individuals brain

ARTICLE CONTINUES BELOW ADVERTISEMENT

Our study is really examining how this gene affects brain development, Nopoulos said. And in that context, were examining how we would deliver a gene therapy and how that would impact brain development.

We certainly dont want to prevent the disease only to cause problems for brain development.

The gene that causes Huntingtons, called HTT, is key for an area of the brain called the striatum, which helps control voluntary movement, among other functions. Through their study, Nopoulos and other researchers on the project hope to understand what consequences could result from the therapy on development.

If we were to give the gene modifying therapy too early, it could prevent maximum brain function, she said.

Nopoulos has been studying this question for 10 years at the UI and will continue that work under the newly funded project, called Children to Adult Neurodevelopment in Gene-Expanding Huntingtons disease.

The $18 million grant from the national institute is a renewal of the same study from the UI, allowing Nopoulos and other researchers to expand the scope and size of the original study by including five times as many participants from five sites across the United States.

In addition to the UI, those sites will include the Childrens Hospital of Philadelphia, Columbia University in New York, the University of California, Davis and the University of Texas in Houston.

All subjects in the study, who are between the ages of 6 and 30, have a parent with Huntingtons, which means they are 50 percent at risk for developing the genetic disorder sometime in their lifetime.

Nopoulos said the test subjects dont know if they carry the genetic marker for the disease.

ARTICLE CONTINUES BELOW ADVERTISEMENT

Weve been doing this for 10 years, and Im always amazed at how strong these kids are, Nopoulos said. The study gives them meaning and an opportunity to help gain knowledge about the disease their parent is going through.

A lot of these children really take on the altruism of wanting to give back to the community, even when they know theyre at risk themselves, she said.

Comments: (319) 368-8536; michaela.ramm@thegazette.com

See the original post:
University of Iowa researcher gets $18 million to study Huntington's disease - The Gazette

In an effort to understand aging, researchers from Stanford University and colleagues around the world analyzed almost 3,000 proteins in the blood of more than 4,000 people ages 18 to 94. They published their research in the journal Nature Medicine.

When we went into this, we assumed you aged gradually, so we would see these changes taking place relatively steadily as individuals get older, said Tony Wyss-Coray, professor of neurology at Stanford University, senior author of the study.

That isnt what they found, however. They found that the proteins appear to change in three distinct waves, with the first occurring during our 30s, peaking around age 34.

Then we found a second wave around 60, and then we found a third one, the most prominent one, really around 80 years of age, Wyss-Coray said.

The researchers are dubbing this a proteomic clock, that somewhat accurately predicts an individuals age.

One of the reasons for the research was the insight that by placing the blood of younger mice into older mice, the older mice appeared to grow youngerthe reverse happened, toothe blood from older mice aged younger mice. So, whats in the blood of different-aged animals (including people) that is making these changes for better or worse?

Another fact Wyss-Coray and his team knew was that in the blood proteins of people with Alzheimers disease, the biggest differences werent between Alzheimers patients and healthy people of the same age, but between people of different ages.

The researchers winnowed the thousands of proteins they were looking at down to 373 whose levels appeared to be predictive of age.

Wyss-Coray notes that most of the proteins found in the blood derive from other tissues. So we can start to ask where these proteins come from and if they change with age.

For example, proteins that trace back to the liver would suggest the liver is aging. Or if they derive from the kidney, the kidney is aging. Wyss-Coray hopes to eventually be able to analyze blood protein patterns to create a personalized aging clock where I can tell you, based on the composition of your blood, your kidney seems to be aging faster than it should.

And perhaps, if enough information is found, similar to the mouse aging experiments, it might be possible to isolate proteins that contribute to the effectpreferably the one that keeps you young, not makes you old.

Some companies went into the business of selling blood transfusion plasma from young people as an anti-aging potion. The U.S. Food and Drug Administration (FDA), in February 2019, issued warnings to consumers and health care providers against this, pointing out that the FDA did not test these in order to confirm therapeutic benefit or safety.

We strongly discourage consumers from pursuing this therapy outside of clinical trials under appropriate institutional review board and regulatory oversight, the agency said in a statement from then-Commissioner Scott Gottlieb.

Gottlieb added, Our concerns regarding treatments using plasma from young donors are heightened by the fact that there is no compelling clinical evidence on its efficacy, nor is there information on appropriate dosing for treatment of the conditions for which these products are being advertised. Plasma is not FDA-recognized or approved to treat conditions such as normal aging or memory loss, or other diseases like Alzheimers or Parkinsons disease.

The agency warned of possible risks of infectious, allergic, respiratory and cardiovascular problems from the treatments.

Meanwhile, groups like Wyss-Corays and others are attempting to identify which proteins are most effective and whether the proteins themselves are active in staying young or just markers of something else.

Irina Conboy, a researcher at the University of California, Berkeley, published research in the journal Aging in August 2019, that analyzed a protein known as TGF-beta, which is associated with aging. Her experiments in laboratory mice hint that by blocking TGF-beta, aging effects can be slowed.

Wyss-Coray has founded a biotech company, Alkahest, that is researching blood plasma infusions in Alzheimers disease, as well as other applications of blood plasma infusions. At the recent 12th Clinical Trials on Alzheimers Disease conference the company gave an oral presentation of Phase II trial of GRF6019 in mild-to-moderate Alzheimers disease. The Phase IIa trial was completed and patients were randomized and treated with 100mL or 250mL of GRF6019 for five days during Week 1 and again for five consecutive days until Week 13 with a treatment-free interval of 11 weeks after each dose.

GRF6019 and another of its products, GRF6021, are proprietary plasma fractions developed and provided by Grifols. In animal models the plasma fractions improved neurogenesis as well as age-related learning and memory deficits. They also decreased neuroinflammation.

Toshiko Tanaka, an investigator at the National Institute on Aging was the lead author of a study published in 2018 that leveraged similar techniques and also found proteins associated with aging. One of the great things about these advancements, she told NPR, is its becoming a lot cheaper to measure a lot of these molecules, so bigger studies and more studies can assess the same proteins.

At this time, the research is a way off from specifically identifying proteins associated with aging, but its a very good first step.

Paola Sebastiani, a biostatistician at Boston University who has also conducted research on aging and blood proteins, told NPR that, For a long time we have focused, in the field of healthy aging, on genetics.

However, we generally cant modify genesalthough gene therapies and genome editing techniques such as CRISPR are starting to do just that. Sebastiani points out that one of the interesting aspects of these blood proteins is they can be inhibited or blocked or modified using a variety of biochemical and small molecule process that theoretically be used to improve health and slow the aging process.

The rest is here:
Aging in Waves: New Findings on Aging-Related Proteins in the Blood - BioSpace

DUBLIN, Dec. 17, 2019 /PRNewswire/ -- The "Red Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

This study on the red biotechnology market provides readers with a holistic market overview, through an extensive analysis of the market.

The report analyzes the market with regards to the historical and current data to provide a forecast for the period of 2019-2027. Actionable insights and findings pertaining to the red biotechnology market help report readers take major business decisions that support their long-term business growth.

The study includes the compilation of the assessment of significant market dynamics such as key industry trends and major developments carried out by leading players, along with a detailed competitive assessment. The study is divided into key sections to provide readers with an individual understanding of the various aspects of the red biotechnology market.

Key Questions Answered

Key Topics Covered

1. Global Red Biotechnology Market - Preface1.1. Market Definition and Scope1.2. Market Segmentation1.3. Key Research Objectives1.4. Research Highlights

2. Assumptions and Research Methodology2.1. Red Biotechnology Market Definition2.2. Red Biotechnology Market Taxonomy

3. Executive Summary : Global Red Biotechnology Market3.1. Introduction3.1.1. Definition3.1.2. Industry Evolution/Developments3.2. Overview3.3. Market Dynamics3.3.1. Drivers3.3.2. Restrains3.3.3. Opportunities3.4. Global Red Biotechnology Market Analysis and Forecast, 2017-20273.5. Market Revenue Projections (US$ Bn)4. Market Outlook4.1. Pipeline Analysis4.2. Mergers & Acquisitions

5. Global Red Biotechnology Market Analysis and Forecast, by Application 5.1. Introduction5.2. Key Findings/Developments, by Type 5.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2017-20275.3.1. Biopharmaceutical Production5.3.2. Gene Therapy5.3.3. Pharmacogenomics5.3.4. Genetic Testing5.4. Global Red Biotechnology Market Attractiveness Analysis, by Application

6. Global Red Biotechnology Market Analysis and Forecast, by End-user 6.1. Introduction6.2. Key Findings/Developments, by End-user 6.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2017-20276.3.1. Pharmaceutical Industry 6.3.2. CMO & CRO6.3.3. Research Institutes6.3.4. Others 6.4. Global Red Biotechnology Market Attractiveness Analysis, by End-user

7. Global Red Biotechnology Market Analysis and Forecast, by Region/sub-Region7.1. Key Findings/Developments 7.2. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Region/Sub-Region, 2017-20277.2.1. North America7.2.2. Europe7.2.3. Asia-Pacific 7.2.4. Latin America7.2.5. Middle East & Africa (MEA)7.3. Global Red Biotechnology Market Attractiveness Analysis, by Region/Sub-Region

8. North America Red Biotechnology Market Analysis and Forecast

9. Europe Red Biotechnology Market Analysis and Forecast

10. Asia-Pacific Red Biotechnology Market Analysis and Forecast

11. Latin America Red Biotechnology Market Analysis and Forecast

12. Middle East & Africa Red Biotechnology Market Analysis and Forecast

13. Competition Landscape13.1. Market Player - Competition Matrix 13.2. Market Share Analysis, by Company (2018)13.3. Company Profiles13.3.1. Pfizer Inc.13.3.2. Biogen Inc.13.3.3. Amgen Inc.13.3.4. AstraZeneca PLC13.3.5. Gilead Sciences Inc.13.3.6. Celgene Corporation13.3.7. F. Hoffmann-La Roche Ltd.13.3.8. Merck KGaA13.3.9. Regeneron Pharmaceuticals Inc.13.3.10. Takeda Pharmaceutical Company Limited

For more information about this report visit https://www.researchandmarkets.com/r/xf6hwp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original here:
Insights Into the World's Red Biotechnology Market, 2017-2019 & 2027 - Emerging Opportunities, Revenue Projections, Leading Players - PRNewswire

Gene therapy, once dismissed as too dangerous, has made a comeback, with two products approved in the U.S. since December 2017 and hundreds more in the pipeline. STATs latest report takes a deep dive into a crucial component of these new treatments: the viral vectors used to deliver gene therapies to cells and organs.

As dozens of new gene therapies near the market, we spoke with academic experts, pioneers in the field, and executives with 18 companies, large and small, to identify the most important challenges surrounding the engineering of better vectors, their safety, effectiveness, efficiency, production, and cost and how key players are thinking about overcoming those hurdles.

These engineered viruses are difficult to manufacture, particularly at the massive scale needed for some indications. Scientists are working hard to bring down the cost and speed up the process of making viral vectors, so that all the patients that could benefit from gene therapy will have access to it.

advertisement

Beyond the introduction, this report has four major components:

The basics of viral vectors and the history of their development;

Major challenges in the development, manufacturing, and testing of viral vectors, and possible solutions;

A close look at the status of gene therapies in 10 disease categories that are advancing through preclinical studies or are being tested in early-stage clinical trials;

And perspective on the U.S. Food and Drug Administrations approach to regulating viral vectors.

The report The STAT guide to viral vectors, the linchpin of gene therapy is intended for anyone with a strong interest in gene therapy, including biotech executives, investors, scientists, lawyers, policymakers, and patients and families interested in learning more. Our aim is to make the problems, stakes, and possibilities clear to everyone.

To buy the full report, please click here.

Go here to read the rest:
New STAT report explores viral vectors, the linchpin of gene therapy - STAT

As 2019 comes to a close, Charles River Laboratories (CRL) has been busy. Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash.

California-based HemaCare is a provider of human-derived cellular products for the cell therapy market. The company provides biomaterials, including a wide range of human primary cell types. Also, HemaCare supplies cell processing services to support the discovery, development, and manufacture of cell therapies, including allogeneic and autologous programs. Combined with CRLs integrated, early-stage portfolio of discovery, safety assessment, and manufacturing support services, the acquisition of HemaCare will create a comprehensive solution for cell therapy developers and manufacturers worldwide to help accelerate their critical programs from basic research and proof-of-concept to regulatory approval and commercialization, the company said in its announcement. For its clients, CRL believes the addition of HemaCare will enhance client retention and accelerate biopharmaceutical clients speed-to-market.

As more and more cell and gene therapies are expected to be approved over the next several years, CRL believed now was the time to push into the space. James C. Foster, president and chief executive officer of CRL, said that in order to continue to enhance the companys abilities to support the research efforts of its clients, CRL needed to expand its scientific capabilities into this high-growth market.

HemaCare advances the development of life-saving cell therapies through the use of its high-quality cellular products that represent critical inputs to these therapeutics. The addition of HemaCares innovative cell therapy products and services to our integrated, early-stage solutions will create a unique, go-to partner for clients to work with Charles River across a comprehensive cell therapy portfolio from idea to novel therapeutic, Foster said in a statement.

Foster added that HemaCares expertise is well-recognized and pointed to the fact the company has worked on all of the cell therapy drugs approved by the U.S. Food and Drug Administration to date. He said the addition of HemaCare will enhance CRLs value proposition for its clients and will also drive profitable revenue and generate value for the companys shareholders.

The proposed purchase price of $380 million equates to $25.40 per share of HemaCare. That represents a 27% premium to HemaCares closing price on Dec. 13. The acquisition is expected to close early in the first quarter of 2020.

For CRL, the acquisition of HemaCare follows a strategic partnership forged with Bit Bio earlier this month. Bit Bio reprograms human cells for use in research, drug discovery, and cell therapies. Through its partnership with Bit Bio, CRL said it will offer clients access to an expanding suite of authentic human cells through their use in target discovery, validation and screening services.

Read the original:
Charles River Laboratories Moves into Cell Therapies with $380 Million Acquisition of HemaCare - BioSpace

The research study on Global Gene Therapy market 2019 presents an extensive analysis of current market size, drivers, trends, opportunities, challenges, as well as key market segments. Further, it explains various definitions and classification of the Gene Therapy industry, applications, and chain structure.

In continuation of this data, the Gene Therapy report covers various marketing strategies followed by key players and distributors. Also explains marketing channels, potential buyers and development history. The intent of global Gene Therapy research report is to depict the information to the user regarding market forecast and dynamics for the upcoming years.

The study lists the essential elements which influence the growth of Gene Therapy industry. Long-term evaluation of the worldwide market share from diverse countries and regions is roofed within the report. Additionally, includes type wise and application wise consumption figures.

After the basic information, the global Gene Therapy Market study sheds light on the technological evolution, tie-ups, acquisition, innovative business approach, new launches and revenue. In addition, the Gene Therapy industry growth in distinct regions and R&D status are enclosed within the report.

The study also incorporates new investment feasibility analysis of Gene Therapy. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Gene Therapy market.

Highlights of Global Gene Therapy Market Report:

Table of Content:01: Gene Therapy Market Overview02: Global Gene Therapy Sales, Revenue (value) and Market Share by Players03: Gene Therapy Market Sales, Revenue (Value) by Regions, Type and Application (2014-2018)04: Region wise Top Players Gene Therapy Sales, Revenue and Price05: worldwide Gene Therapy Industry Players Profiles/Analysis06: Gene Therapy Manufacturing Cost Analysis07: Industrial Chain, Gene Therapy Sourcing Strategy and Downstream Buyers08: Gene Therapy Marketing Strategy Analysis, Distributors/Traders09: Gene Therapy Industry Effect Factors Analysis10: Global Gene Therapy Market Forecast (2019-2029)11: Gene Therapy Research Findings and Conclusion12: Appendix

This post was originally published on Market Research Sheets

Continued here:
Gene Therapy Market by Industry Size, Share, Competitors' Landscape, And Segmentation Including: Regional Segment, Type Segment, Industry Segment,...

Sarepta Therapeutics (SRPT) recently publicized that the FDA approved Vyondys 53. This approval came only a few months after the drug received a CRL due to concerns over the risk of infection at the infusion site and renal toxicity. The company filed an appeal and it looks like the matters raised in the CRL were quickly resolved. SRPT has shot up over 30% following the news, and but is still trading well under its 52-week high of $158.80. Not only is this approval important for the companys commercial outlook, but it also reinstalls some confidence in the companys gene therapy pipeline and technology. Despite the recent big move to the upside, I still see SRPT to be discounted at this current price and could be a lucrative long-term investment.

I intend to provide a brief background on Vyondys 53 and its journey through the FDA. In addition, I discuss why I still think SRPT is still worth a speculative investment. Finally, I reveal my plans for my SRPT position for 2020.

Vyondys 53 is similar to Sareptas Exondys 51, which allows the skipping over gene mutation that inhibits patients with DMD from producing dystrophin. Exondys 51 works in roughly 13% of the roughly 15K boys in the U.S. who have DMD. Although Vyondys 53 will only take aim at 8% of the DMD population, it is still the second most common DMD mutation. Vyondys 53 will be priced at $300K a year per 20kg, so some patients could be paying over $1M a year for the treatment.

Figure 1: DMD and Exon Skipping (Source: SRPT)

Vyondys 53 was an accelerated approval, so Sarepta will need to conduct post-marketing studies to confirm its safety and efficacy. Sarepta is already enrolling patients in their confirmatory trial and should have the results in 2024.

Back in August, Vyondys 53 received a CRL primarily due to renal toxicity concerns from pre-clinical data...at a dose 10 times greater than what was submitted in the NDA. I have seen some ridiculous reasons for the FDA sending a CRL, but citing preclinical data at 10x dosage was by far the most outrageous. I have to imagine almost every drug or therapy is toxic at a 10x dosage. To be honest, I was convinced the FDAs CRL was more than suspicious, but it appears they have backtracked and granted Sarpetas appeal.

Not only is this a win for Sarepta, but it is also a win for gene therapy and the companies who are attempting to develop gene therapeutics. Most of the leading gene therapy stocks took a hit following the CRL as the prospects for gene products making through the FDA's scrutiny seemed to be degrading. Now that the FDA has recognized their error, investors should have renewed confidence in the regulatory and commercial outlook for gene therapies in the US.

As I mentioned before, Vyondys 53 approval has reassured the market that Sarepta's platform and technology are capable of producing more marketable gene therapies. Looking at Sarepta's pipeline (Figure 2) the company can see a great amount of potential value.

Figure 2: SRPT Pipeline (Source: SRPT)

Sarepta is now pushing their next-generation PPMO RNA platform. The company will have safety and dosing insight in 2020. If Sareptas PPMO shows encouraging results they plan to conduct additional research on new therapeutic targets using the PPMO platform.

In terms of microdystrophin manufacturing, the company has completed building out of Sareptas single-use microdystrophin manufacturing facility in Lexington, Massachusetts. In addition, the company also has dedicated suites with Paragon in Maryland, which is expected to have a greater capacity than the Lexington facility. So, it appears the company will have the capacity to support more commercial products as they continue to cross the FDA finish line.

Not only is the company have a strong R&D department, but their commercial team has demonstrated some success with payers, physicians, and prospective patients. The company has recorded revenue growth since Q4 of 2016 and is expected to continue to record sequential revenue growth for the next 7 years (Figure 3).

Figure 3: SRPT Estimated Annual Revenue Growth (Source: Seeking Alpha)

Exondys 51 continues to perform well with Q3 sales above consensus at $99M, which was a 26% increase over Q3 of last year. This prompted the company to boost the 2019 revenue guidance range from $365M to $375M to a range of $370M to $380M for Exondys 51. In fact, Exondys 51 numbers have grown quarter-over-quarter for over the past 3 years.

Another reason to be bullish on SRPT is the companys current financial position, which over $1B. Their healthy cash position will allow the company to fast-track Sareptas growing pipeline and support company operations. Indeed, the company revealed a net loss of $126.3M in Q3, so the company is still incinerating cash. However, Sarepta recently announced an agreement with Pharmakon Advisors, LP, for $500M to be given two $250M tranches. The first will be obtainable after closing and the second will be available at Sareptas option until December 31st of next year. This recent funding not only allows the company to keep the pedal down on R&D, but it was a non-dilutive fundraising event.

What is more, one of Sarepta's potential competitors Wave Life Sciences (WVE) recently announced that it has decided to drop its DMD exon skipping programs. This decision comes after some disappointing data for their exon 51 and exon 53 skipping product candidates. Not only has Sarepta lost a potential competitor, but Wave's exit from DMD shows how advanced Sarepta's exon-skipping products really are.

As a result, I believe Sarepta has the products, pipeline, commercial ability, manufacturing capacity, and the financials to execute on their long-term growth strategy. Returning to figure 3, I expect Sarepta to follow this growth trajectory for the next several years, and will rapidly grow into its current valuation. Sareptas aspiring strategy has created one of the biggest multi-platform genetic medicine pipelines in biotech, which contains over 25 active programs across Sareptas RNA and gene therapy platforms that will be providing multiple catalysts in the coming years. Considering the points above, I still see SRPT to be worthy of speculative buy that could become a lucrative long-term investment.

What's My Plan?

I took a leap of faith following the CRL and added to my speculative SRPT position. Now that I am in the green, I plan on holding my shares for at least four more years and will consider holding if the company is able to get their current pipeline across the finish line. In the meantime, I am going to take advantage of SRPT's volatility and will wait for a pull-back to add to my position. However, I am not going to go all-in until the company has completed their confirmatory studies.

What is more, Sareptas approval has bolstered my confidence in my other gene therapy investments and will look to add to those positions in the near future.

Disclosure: I am/we are long SRPT. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Original post:
Sarepta Therapeutics: FDA Approval Reinstalls Confidence In The Pipeline - Seeking Alpha

The research report Cancer Gene Therapy Market Global Industry Analysis 2019 2025 offers precise analytical information about the Cancer Gene Therapy market. The report identifies top players in the global market and divides the market into several parameters such as major drivers market strategies and imposing growth of the key players. Worldwide Cancer Gene Therapy Industry also offers a granular study of the market dynamics, segmentation, revenue, share forecasts and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Cancer Gene Therapy industry.

This Cancer Gene Therapy market report bestows with the plentiful insights and business solutions that will support our clients to stay ahead of the competition. This market report contains categorization by companies, region, type, and application/end-use industry. The competitive analysis covered here also puts light on the various strategies used by major players of the market which range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and many others that leads to increase their footprints in this market. The transparent research method carried out with the right tools and methods makes this Cancer Gene Therapy market research report top-notch.

Interesting? Apply for a sample report: http://www.marketsnresearch.com/request-for-sample.html?repid=51038

Competitive Landscape

Global Cancer Gene Therapy market is highly split and the major players have used numerous tactics such as new product launches, acquisitions, innovation in products, expansions, agreements, joint ventures, partnerships, and others to increase their footprints in this market.

Key players profiled in the report include: Adaptimmune, GlaxoSmithKline, Bluebirdbio, Merck, Celgene, ShanghaiSunwayBiotech, BioCancell, ShenzhenSiBionoGeneTech, SynerGeneTherapeutics, OncoGenexPharmaceuticals, GeneluxCorporation, CellGenesys, Advantagene, GenVec, BioCancell, Celgene, EpeiusBiotechnologies, IntrogenTherapeutics, ZiopharmOncology, ShenzhenSiBionoGeneTech, AltorBioscience

Market Segmentation

Cancer Gene Therapy Market report segmentation on Major Product Type:GeneInducedImmunotherapy, OncolyticVirotherapy, GeneTransfer

Market by Application: Here, various application segments of the global Cancer Gene Therapy market are taken into account for the research study.

Hospitals, DiagnosticsCenters, ResearchInstitutes

Enquire Here For Queries Or Report Customization: http://www.marketsnresearch.com/inquiry-for-buying.html?repid=50621

Regional Analysis

The Cancer Gene Therapy market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as North America, Europe, Asia Pacific, Middle East, South America, and Middle East & Africa (MEA). Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the market report.

Key Questions Answered in Global Cancer Gene Therapy Market Report:-

What will the market growth rate, overview, and analysis by type of global Cancer Gene Therapy Market in 2026?

What are the key factors driving, analysis by applications and countries Global Cancer Gene Therapy Market?

What are dynamics, this summary includes analysis of the scope and price analysis of top players profiles of Global Cancer Gene Therapy Market?

Who are the opportunities, risk and driving forces of the global Cancer Gene Therapy Market?

Who are the opportunities and threats faced by the vendors in the Global Cancer Gene Therapy Market?

What are the Global Cancer Gene Therapy market opportunities, market risk and market overview of the Market?

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Read the original:
Cancer Gene Therapy Market Expected to Deliver Dynamic Progression until 2028| Adaptimmune, GlaxoSmithKline, Bluebirdbio, Merck - E-Industry News

The global Cancer Gene Therapy market report offers a significant assistant that helps the reader to get a thorough understanding of the value chain analysis. The latest trends, developments, promotion, strategies, and many more provide an uphold success. To reveal the general market trends coupled with conditions and variable tendencies the global Cancer Gene Therapy market report acts as a bible for the reader. The report offers reliable information in relation to the market with proper planning techniques. This report is presented in a precise fashion that records state-of-art information regarding preferences, consumers demands, attitudes, and variable tendencies about the specific product pipelines. The report also aims to offer an open discussion about the global Cancer Gene Therapy market.

About Cancer Gene Therapy Market

Gene therapy is the insertion of a functional gene into the cells of a patient to correct an inborn error of metabolism, in order to alter or repair an acquired genetic abnormality, and to provide a new function to a cell. Owing to high success rate throughout the preclinical and clinical trials, cancer gene therapy is gaining popularity. Improvised technological advancements, increased adoption of developing genomic technologies such as next generation sequencing (NGS) and high density micro array are some of the major factors that will drive the global cancer gene therapy market in next upcoming years. Cancer cells can be differentiated from their usual neighbors on the basis of specific phenotypic changes, such as rapid division rate, attack of new cellular areas, high metabolic rate, and altered shape.

For Better Understanding, Try Sample PDF Brochure of Report (including full TOC, Tables and Figures) @https://www.esticastresearch.com/report/cancer-gene-therapy-market/#request-for-sample

The insights of the report cover the wide spectrum of the global Cancer Gene Therapy market. With deep insights the reader gets the feasibility while reading that focuses upon the market dynamics governing the trajectory. The in-depth analytical study conducted by the researchers offers strengthens the decision making of the specific market and provoke the analysts to come up with the solution. The report further includes figures and stats coupled with significant compound growth. The compound growth rate directs the reader or analyst to envisage the market growth in base year and forecast time frame.

Competitive Landscapes:

The competitive landscapes are a must-include chapter involving the global players that withstand the competition for the global Cancer Gene Therapy market. This assures the market participants to develop effective strategies to set a benchmark to adopt a significant market position. Further, a competitive environment helps them to determine not only potential advantages but also varied obstacles for the global Cancer Gene Therapy market. In this chapter, the players can examine various strategies and analyze the competitiveness among the players.

List of the Key Players Cited in the Report:

OncoGenex PharmaceuticalsSynerGene TherapeuticsShenzhen SiBiono GeneTechBioCancellShanghai Sunway BiotechCelgeneMerckBluebird bio Inc.GlaxoSmithKlineAdaptimmune

Market Segmentation

On the basis of types, the global Cancer Gene Therapy market is fragmented into

Product 1Product 2

Based on applications, the global Cancer Gene Therapy market is split into:

HospitalsDiagnostics CentersResearch Institutes

With the successive chapters of the Cancer Gene Therapy market, the report further throws the spotlight upon the thorough assessment of the segments at the global outlook. This supports the reader to get a view about the products pipelines, technology, services, end-users, and regions in the overall market. The segment analysis chapter further involves the factors responsible for driving the market on one side while restraining the market on the other side.

Inquire more or share questions if any before the purchasing this report: https://www.esticastresearch.com/report/cancer-gene-therapy-market/#customization

Regional Segmentation

With a wide trend and factors influencing the market that directs regional as well as the primary direction of growth are swung by local market players and unique market drivers. The market study is uplifted at regional as well as country level. This helps to determine the past record and future records through revenue coupled with volume price analysis to involve the region-wise leaders based on the market share and revenue.

Major geographies covered in the report includeNorth America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Sub-regions includes

The years that were considered for the study of this report are the following:

The study objectives are:

Reasons to buy the report:

1055 West 7th Street,

Los Angeles, CA 90017 (P) US

phone 213-935-7207

print (213) 935-7208

Email help@esticastresearch.com

See the article here:
Cancer Gene Therapy Market 2019| Key Players, Industry Share, Trends, Growth Analysis, Regional Demand and Future Insights by 2026 - Techi Labs

"Our impressive portfolio of life sciences companies underscores the tremendous opportunity for this industry in Central Ohio."

COLUMBUS, Ohio (PRWEB) December 17, 2019

Today, Rev1 Ventures, the investor startup studio that combines capital and strategic services to help startups scale and corporations innovate, is announcing the launch of its second fund focused on life sciences companies. The $15MM Rev1 Catalyst Fund II with investment from The Ohio State University, Nationwide Childrens Hospital and Rev1 is three times the size of the first Life Sciences fund and aims to deliver critical investment capital and support for research-based spinouts and healthcare innovators. As a result of the success of the Rev1 Life Sciences Fund I, which has helped industry trailblazers commercialize technologies and build successful companies bringing novel therapies and solutions to the market, this fund will continue to help Rev1 fulfill its mission to propel the creation of high growth companies in the region.

"Our impressive portfolio of life sciences companies underscores the tremendous opportunity for this industry in Central Ohio, said Tom Walker, president and CEO of Rev1 Ventures. We are proud to help innovators fulfill their potential and bring life-saving technologies and therapies to more people. By aligning champions of healthcare innovation, including prominent research institutions like The Ohio State University and Nationwide Childrens Hospital, we are helping to foster life sciences innovation and support entrepreneurs and scientists as they build and grow new companies. The Rev1 Catalyst Fund II is dedicated to expanding the infrastructure to support life sciences and attracting talent and like-minded investors to fuel commercialization.

The Rev1 Life Sciences Fund I supports an impressive portfolio of companies driving the creation of innovative therapies and solutions, and has generated more than $250MM in exits, including the recent acquisitions of Celenex and Myonexus.

Ohio State is committed to supporting our accomplished researchers at every point along the innovation pipeline, said Cheryl Turnbull, senior director for new ventures at Ohio State. Catalyst Fund II supports Ohio States land grant mission and will help advance the promising life sciences technologies being developed at Ohio State and in Columbus, accelerating medical breakthroughs to market where they can have a positive impact on people throughout the world.

We have many significant success stories about the power of this approach--from the worlds first digital pathology cloud-based platform, Deep Lens, to Milo Biotechnology, a startup working to reverse muscular dystrophy using gene therapy, said Matt McFarland, vice president of commercialization and industry relations at Nationwide Children's Hospital. Myonexus, a Nationwide Childrens spinout that is developing the first-ever corrective gene therapy for limb-girdle muscular dystrophies, was recently acquired by Sarepta Therapeutics. Columbus has the foundational elements in place, so we anticipate this hotbed of activity will only get more robust.

Rev1 and Nationwide Childrens Hospital have been paramount to our success as well as to our ability to take a development and build a business around it, said Dave Billiter, co-founder and CEO of Deep Lens. In this field, it is critical that your investors and partners understand the industry, your potential, your market. The participation of these institutions and the fact that they are in our own backyard, is truly impacting lives and changing healthcare.

For more information about the fund and to learn more about the life sciences startups working with Rev1 Ventures, visit: https://www.rev1ventures.com/our-companies/.

About Rev1 VenturesRev1 Ventures is the investor startup studio that combines capital and strategic services to help startups scale and corporates innovate. Based in the Midwest, and in the number one city for scaling startups, Rev1 aligns innovators and founders with corporate and research partners to access customers and markets, helping entrepreneurs build great companies. With a proven track record of identifying, guiding and investing in high potential startups, Rev1 helps companies solve real problems for markets in need of real solutions. Rev1 has $100MM in capital under management, providing a capital continuum from corporate and community partners, as well as the Ohio Third Frontier. Rev1 is the most active seed investor in Ohio five years running, according to Pitchbook. For more information, visit http://www.rev1ventures.com.

About The Ohio State UniversityThe Ohio State University was founded in 1870 following the Land-Grant College Act of 1862. Classes began in the fall of 1873 with 24 students. The first class of six men graduated in 1878, followed by the first woman graduate in 1879. Today, Ohio State is among the largest and most respected public research universities in the nation, with more than 66,000 students on six campuses. The spring 2017 graduating class of over 11,500 was the largest in school history. Ohio State is known best for its vibrant student experience, research excellence, athletic prowess and highly engaged Buckeye family. The true strength of Ohio State is its people. Buckeye Nation includes more than 45,000 faculty and staff as well as 550,000 alumni living and working in 170 countries across the globe.

About Nationwide Childrens HospitalNamed to the Top 10 Honor Roll on U.S. News & World Reports 2019-20 list of Best Childrens Hospitals, Nationwide Childrens Hospital is one of Americas largest not-for-profit freestanding pediatric health care systems providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease. Nationwide Childrens has a staff of more than 13,000 providing state-of-the-art pediatric care during more than 1.5 million patient visits annually. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Childrens physicians train the next generation of pediatricians and pediatric specialists. The Abigail Wexner Research Institute at Nationwide Childrens Hospital is one of the Top 10 National Institutes of Health-funded freestanding pediatric research facilities. More information is available at NationwideChildrens.org.

Share article on social media or email:

Originally posted here:
Rev1 Ventures Launches $15MM Fund with The Ohio State University and Nationwide Children's Hospital to Support Research-based Healthcare Innovation -...

Coherent Market Insights released a new market study on 2018-2026 Cell and Gene Therapy Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2018-2026 Cell and Gene Therapy Market Growth Forecast till 2026*.

The Cell and Gene Therapy Market research report covers the present scenario and the growth prospects of the global Cell and Gene Therapy industry. The report enlists several important factors, starting from the basics to advanced Market intelligence which plays a crucial part in strategizing.

Get Free Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2475

Key companies (manufacturing situations, size and production, product specifications etc.) Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST.

Cell and Gene Therapy Market Report provides key statistics on the market status of the Cell and Gene Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Cell and Gene Therapy industry. The Cell and Gene Therapy Market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market.

Cell and Gene Therapy Market report analyses the Market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and Market demand and supply scenarios.

Regions of Cell and Gene Therapy Market:

North America: United States, Canada, Mexico

Europe: Germany, France, UK, Russia, Italy, Rest of Europe

Middle East Africa: Turkey, Egypt, South Africa, GCC Countries, Rest of Middle East & Africa

Asia-Pacific: China, India, Australia, Japan, South Korea, Indonesia, Malaysia, Philippines, Thailand, Vietnam

Download Free PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2475

In the end, the report makes some important proposals for a new project of Cell and Gene Therapy Industry before evaluating its feasibility. Overall, the report provides an in-depth insight into the global Cell and Gene Therapy industry covering all important parameters.

The Report provides a detailed Cell and Gene Therapy Industry overview along with the analysis of industrys gross margin, cost structure, consumption value, and sale price, Processing Techniques, Network Management, Services Offered, Related Software Market, Social Media Marketing, Cost Structure, Supply Chain, Development Management Techniques, Retailers Analysis, Financial Support, business Strategies, Marketing Channels, Market Entry Strategies, Industry Development Challenges and Opportunities, Investment Plans, Economic Impact on Cell and Gene Therapy Market.

This report can be customized to meet the desired requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Ask Query for more details @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2475

ABOUT USCOMPANY OVERVIEW

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market.

Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module. This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future.

See the rest here:
Rapid Expansion Projected for Cell and Gene Therapy Market by 2026 - Galus Australis